Publications by authors named "Les Noe"

Claim this Profile
B
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Sanjay Merchant, Les L Noe, Andrew Howe, Steve Duff, Joe Gricar

Clin Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis.
Norman Zinner, Les Noe, Lawrence Rasouliyan, Thomas Marshall, M Christopher Runken

Am J Geriatr Pharmacother· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
James F Donohue, Nicola A Hanania, Ronald L Ciubotaru, Les Noe, David J Pasta

Clin Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reimbursement and economic factors influencing dialysis modality choice around the world.
Paul M Just, Frank Th de Charro, Elizabeth A Tschosik, Les L Noe, Samir K Bhattacharyya

Nephrol Dial Transplant· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Norman Zinner, Les Noe, Lawrence Rasouliyan, Thomas Marshall, Raafat Seifeldin

Curr Med Res Opin· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The implications of poor medication persistence with treatment for overactive bladder.
Les Noe, Robyn Sneeringer, Bimal Patel, Todd Williamson

Manag Care Interface· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacoeconomic model comparing two long-acting treatments for overactive bladder.
Les Noe, Russell Becker, Todd Williamson, Donny Chen

J Manag Care Pharm· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis